You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.

    SBC: NEURODON, LLC            Topic: NIDDK

    The overall goal of this collaborative project between Neurodon and Indiana University School of Medicine is the development of compounds that will offer disease-modifying treatments for type 1 (T1D) and type 2 diabetes (T2D) mellitus, a sorely unmet need. In this initial STTR project, we will use our expertise in medicinal chemistry, cell biology, and diabetes pathophysiology to functionally test ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia

    SBC: FGF Therapeutics INC.            Topic: NIAMS

    Abstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Virtual Reality Facilitation of Recovery from Opioid Use Disorder

    SBC: RELATE XR, LLC            Topic: NIDA

    PROJECT SUMMARY / ABSTRACT This Phase I project is a pilot randomized clinical trial designed to show commercial potential for a novel virtual reality intervention in preparation for Phase II development. We propose testing our adjunctive intervention for efficacy on reducing opioid use and increasing abstinence in early recovering opioid use disorder (OUD) persons, with concomitant increases in s ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer

    SBC: Kovina Therapeutics Inc.            Topic: NCI

    ABSTRACT “High-risk” human papillomavirus (HPV) types such as 16 (HPV-16) are identified in the majority of HPV- associated pre-malignant and malignant pathologies of cervical, anogenital, and oropharyngeal epithelia. The E6 protein is essential for viral replication. Structure-based computational screening followed by design and synthesis of derivatives led to the identification of a series o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Mitofusin Agonists to Treat Neurodegenerative Disease

    SBC: Mitochondria in Motion, Inc.            Topic: 104

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government